Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more
Reviva Pharmaceuticals Holdings Inc. (RVPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.229x
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has a cash flow conversion efficiency ratio of -1.229x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.59 Million) by net assets ($4.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Reviva Pharmaceuticals Holdings Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Reviva Pharmaceuticals Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SEC
KQ:081180
|
-0.020x |
|
Silver X Mining Corp
OTCQB:AGXPF
|
0.003x |
|
Alaska Silver Corp.
F:MK7
|
-0.616x |
|
Bioptik Technology
TWO:4161
|
0.038x |
|
San Neng Group Holdings Co Ltd
TW:6671
|
0.043x |
|
RAIZ Invest Ltd
AU:RZI
|
0.070x |
|
Societe d Exploration Miniere Vior Inc
V:VIO
|
0.001x |
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
0.004x |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |